Month: <span>August 2019</span>

Aevi Genomic Medicine Signs an Option and License Agreement with

Shots: AstraZeneca to receive option exercise fee in cash and equity, up to $162M as development & commercial milestones and royalties on global sales Aevi Genomic to get an option to develop & commercialize AstraZeneca’s MEDI2338 and have to exercise the option within five mos. from the effective date of the agreement and will be […]Read More

NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women’s

Shots: NIH has launched LUCA Biologics in Cambridge, Massachusetts focusing on women’s health by initially targeting UTI with its anticipated clinical study and initiation of recruitment of patients in H2’19 LUCA initiates with a strain bank and gene catalog developed over 15yrs. from Gates Foundation and NIH-funded research and has built a metagenomic and metatranscriptomic […]Read More

ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in

Shots: The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients with r/r DLBCL Sophia Genetic will analyze cell-free DNA (cfDNA) samples extracted from blood patients participating in ADC Therapeutics’ Phase II study utilizing Sophia’s technology, […]Read More

AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound

Shots: The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation The P-III PROfound study resulted in meeting its 1EPs i.e, improvement in radiographic PFS in men with mCRPC selected for BRCA1/2 or ATM gene mutations, safety […]Read More

Spring Bank Signs a Research Agreement with the University of

Shots: Spring Bank enters into a collaboration with the University of Texas Southwestern Medical Center for the evaluation of Spring Bank’s STimulator of INterferon Gene (STING) antagonist compounds in autoimmune disease models Spring Bank will evaluate novel STING antagonist compounds in mouse models of autoimmune and inflammatory diseases to meet the unmet medical need for […]Read More

Allergan Reports the Acceptance of EMA’s MAA for Abicipar to

Shots: Molecular Partners announces that EMA has validated the MAA of its partner Allergan for Abicipar to treat patients with nAMD Post-approval, Abicipar will be the first anti-VEGF therapy to maintain vision gains with a 12-week dosing interval. The companies collaborated to advance clinical programs in ophthalmology and to robust pipeline of DARPin drug candidates […]Read More